Brief: Hlb Co Resubmits New Drug Application Of Rivoceranib To Us FDA
12/10/2026 24:58
BRIEF-Hlb Co Resubmits New Drug Application Of Rivoceranib To Us FDA HLB Co Ltd 028300.KQ:
RESUBMITS NEW DRUG APPLICATION OF RIVOCERANIB TO US FDA
Source text: [ID:]
Further company coverage: 028300.KQ
Recent news on HLB
See all newsBrief: Hlb Co Resubmits New Drug Application Of Rivoceranib To Us FDA
Elevar-Hengrui hit with third FDA rejection for liver cancer therapy over manufacturing concerns (updated)
Brief: Elevar Therapeutics' NDA Resubmission For Rivoceranib With Camrelizumab Accepted By FDA
Brief: Elevar Therapeutics Resubmits NDA To U.S. FDA For Camrelizumab Plus Rivoceranib Astreatment For Unresectable Hepatocellular Carcinoma
Brief: Hlb Inc To Acquire 16 Billion Won Worth Of Shares In Neurotobe Pharmaceuticals Inc